Conmed Corp Stock Price, News & Analysis

CONMED Corporation (NYSE: CNMD) reported strong first quarter results for 2023, achieving sales of $295.5 million, a 21.9% increase year over year, with a 25.1% rise in constant currency. Domestic sales grew by 25.4%, while international sales rose 17.8% year over year. However, diluted net earnings per share (GAAP) fell to $0.06, an 87.2% decline compared to Q1 2022. Adjusted diluted net earnings per share decreased by 5.7% to $0.66. The company has raised its full-year revenue guidance to between $1.205 billion and $1.250 billion, up from a previous range of $1.170 billion to $1.220 billion. Additionally, adjusted diluted net earnings per share guidance was increased to a range of $3.30 to $3.50.

CONMED Corporation (NYSE: CNMD) will announce its Q1 2023 financial results on April 26, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss these results. Investors can participate via telephone or listen to a webcast on CONMED's website. The company produces surgical devices for various specialties, including orthopedics and general surgery. Forward-looking statements in the release highlight risks from the ongoing COVID-19 pandemic, which may affect operational performance.

CONMED Corporation (NYSE: CNMD) announced that its Annual Meeting of Stockholders will take place on May 24, 2023, at 1:30 p.m. ET at its headquarters in Largo, FL, and virtually. Shareholders of record by March 28, 2023 can vote. Further details will be in a definitive proxy statement filed with the Securities and Exchange Commission on April 11, 2023, available on CONMED's website.

CONMED specializes in surgical devices for minimally invasive procedures across various medical fields. The company emphasizes its commitment to addressing risks and uncertainties, notably those arising from the ongoing COVID-19 pandemic.

CONMED Corporation (NYSE: CNMD) has announced that Curt R. Hartman, Chair and CEO, along with Todd W. Garner, CFO, will participate in a virtual fireside chat at the KeyBanc Life Sciences and MedTech Investor Forum. This event is scheduled for 9:00 a.m. ET on March 22, 2023. A live audio webcast will be available on the Company’s website, with a replay following the event. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and gastroenterology. For more information, visit www.conmed.com.

CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share. The dividend is payable on April 5, 2023, to shareholders of record as of March 15, 2023. This announcement reflects the company's ongoing commitment to returning value to its shareholders.

CONMED specializes in providing surgical devices and equipment for minimally invasive procedures in various medical specialties, including orthopedics and gastroenterology. Further details can be found on their official website.

CONMED reported Q4 2022 sales of $250.9 million, an 8.4% decline year-over-year, with domestic revenue down 3.9% and international revenue down 13.8%. Diluted net earnings per share (GAAP) rose 14.7% to $0.86, while adjusted earnings fell 60.7% to $0.42. For full-year 2022, sales grew 3.4% to $1,045.5 million. However, the company reported a diluted net loss per share of $2.68, contrasting with earnings of $1.94 in 2021. For 2023, CONMED forecasts revenue between $1.170 billion and $1.220 billion, with adjusted EPS expected at $3.20 to $3.45.

CONMED Corporation (NYSE: CNMD) is set to release its fourth quarter 2022 financial results on February 2, 2023, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the outcomes. Participants can pre-register for the call or access a live webcast on CONMED's website. The company specializes in surgical devices for minimally invasive procedures across various medical fields. The press release includes forward-looking statements regarding the impact of the COVID-19 pandemic on the business and operating volumes.

CONMED Corporation (NYSE: CNMD) has declared a quarterly cash dividend of $0.20 per share. This dividend will be payable on January 5, 2023, to shareholders of record as of December 16, 2022. CONMED specializes in providing surgical devices and equipment for minimally invasive procedures across various medical specialties.

CONMED Corporation (NYSE: CNMD) announced participation in the 34th Annual Piper Sandler Healthcare Conference, with a fireside chat led by Curt R. Hartman and Todd W. Garner on November 30, 2022, at 3:30 p.m. ET. A live audio webcast will be available on the 'Investors' section of their website and will be replayed afterward. CONMED specializes in surgical devices for minimally invasive procedures across various medical specialties, including orthopedics and general surgery. For more details, visit www.conmed.com.